Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin glargine
Drug: insulin aspart

First Posted Date: 2015-04-17

Last Posted Date: 2018-03-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 506

Registration Number: NCT02420262

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec

First Posted Date: 2015-03-18

Last Posted Date: 2019-10-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1262

Registration Number: NCT02392117

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Changing Diabetes in Children

Terminated

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin human

First Posted Date: 2015-03-09

Last Posted Date: 2015-03-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3089

Registration Number: NCT02382757

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

Phase 3

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Drug: somapacitan
Drug: somatropin

First Posted Date: 2015-03-09

Last Posted Date: 2020-07-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 92

Registration Number: NCT02382939

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2014-12-22

Last Posted Date: 2017-09-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1092

Registration Number: NCT02321878

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2014-12-03

Last Posted Date: 2019-03-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7315

Registration Number: NCT02306681

Locations: 🇦🇪
Novo Nordisk Investigational Site, Ajman, United Arab Emirates

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin 338 (GIPET I)

First Posted Date: 2014-12-02

Last Posted Date: 2019-07-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT02304627

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-12-02

Last Posted Date: 2019-06-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 397

Registration Number: NCT02305381

Locations: 🇸🇰
Novo Nordisk Investigational Site, Presov, Slovakia

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: NNC0174-0833

First Posted Date: 2014-11-25

Last Posted Date: 2018-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 54

Registration Number: NCT02300844

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/liraglutide

First Posted Date: 2014-11-21

Last Posted Date: 2017-05-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 420

Registration Number: NCT02298192

Locations: 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy